Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ProQR Therapeutics N.V. (PRQR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.75+0.15 (+1.97%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.60
Open7.70
Bid7.71 x 1100
Ask8.13 x 1000
Day's Range7.44 - 7.96
52 Week Range3.40 - 9.46
Volume395,821
Avg. Volume686,612
Market Cap512.491M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-1.12
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.89
  • GlobeNewswire

    ProQR Announces Highlights from Analyst Event

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth review of the Company’s clinical-stage programs and RNA editing technology platforms. A webcast replay of the event including slides is available from the “Investors & Media” section

  • GlobeNewswire

    ProQR to Webcast Virtual Analyst Event on November 18

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Analyst Event on November 18, 2021, from 12-2pm ET to highlight its clinical stage pipeline programs and the Axiomer® RNA editing platform. ProQR leadership will highlight key advancements from its clinical-stage pipeline, includi

  • GlobeNewswire

    ProQR Announces Upcoming Investor Conferences in November and December

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following upcoming investor conferences: Stifel 2021 Virtual Healthcare Conference Monday, November 15, 11:20-11:50am EST – Fireside chatEvercore ISI 4th Annual HealthCONx ConferenceThursda

Advertisement
Advertisement